The biology and treatment of oligometastatic cancer

Oncotarget

Volumn 6, Issue 11, 2015, Pages 8491-8524

  Reyes, Diane K ^a   Pienta, Kenneth J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Diaspora; Metastasis; Spectrum theory; Therapy; Tumor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DABRAFENIB; DEGARELIX; ERLOTINIB; IPILIMUMAB; NELFINAVIR; PEMBROLIZUMAB; SUNITINIB; TRAMETINIB; TRASTUZUMAB; MICRORNA; RNA;

ARTICLE; BILE DUCT CARCINOMA; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CRYOTHERAPY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC IMAGING; DISEASE FREE INTERVAL; DRUG SAFETY; HUMAN; INOPERABLE CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; METASTATIC MELANOMA; MOLECULAR DIAGNOSIS; NON SMALL CELL LUNG CANCER; NONHUMAN; OLIGOMETASTASIS; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATECTOMY; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOFT TISSUE SARCOMA; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; ANTIBODY SPECIFICITY; BAYES THEOREM; BIOLOGICAL MODEL; CARCINOMA; CLINICAL TRIAL (TOPIC); CRYOSURGERY; EVIDENCE BASED MEDICINE; GENETICS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; MOUSE; NEOPLASM METASTASIS; PATHOPHYSIOLOGY; RADIOSURGERY; RADIOTHERAPY; SARCOMA; SECONDARY; TUMOR ESCAPE;

ANIMALS; BAYES THEOREM; CARCINOMA; CLINICAL TRIALS AS TOPIC; CRYOSURGERY; EVIDENCE-BASED MEDICINE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MELANOMA; MICE; MICRORNAS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; ORGAN SPECIFICITY; RADIOSURGERY; RNA, NEOPLASM; SARCOMA; TUMOR BURDEN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84928738955     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3455     Document Type: Article

References (200)

1. Weigelt B, Peterse JL van't Veer LJ. Breast cancer metastasis:markers and models. Nature reviews Cancer. 2005; 5:591-602.
2. Paget S. Distribution of secondary growths in cancer of the breast. Lancet. 1889; 1:571-573.
3. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Annals of Surgery. 1907; 46:1-19.
4. Tait CR, Waterworth A, Loncaster J, Horgan K, Dodwell D. The oligometastatic state in breast cancer: hypothesis or reality. Breast. 2005; 14:87-93.
5. Ewing J. (1928). MetastasisNeoplastics. (Philadelphia:Saunders) 1928; 77-89.
6. Keynes SGL. (1956). Carcinoma of the breast. Post-Graduate Committee FoM, Dalhousie University. Halifax, ed. The Nova Scotia Medical Bulletin) (St. Bartholomew's Hospital, London: 1956; 162-169.
7. Fisher B. Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture. Cancer research. 1980; 40:3863-3874.
8. Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich JL, Darga TE, Fan H, Karpenko O, Paty PB, Posner MC, Chmura SJ, Hellman S, Ferguson MK, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PloS one. 2012; 7:e50141.
9. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1994; 12:2229-2234.
10. Pienta KJ, Robertson BA, Coffey DS, Taichman RS. The cancer diaspora : Metastasis beyond the seed and soil hypothesis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:5849-5855.
11. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nature reviews Cancer. 2002; 2:563-572.
12. Fidler IJ. The pathogenesis of cancer metastasis : the 'seed and soil' hypothesis revisited. Nature reviews Cancer. 2003; 3:453-458.
13. Corbin KS, Hellman S, Weichselbaum RR. Extracranial oligometastases : a subset of metastases curable with stereotactic radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013; 31:1384-1390.
14. Gupta GP, Massague J. Cancer metastasis : building a framework. Cell. 2006; 127:679-695.
15. Weichselbaum RR, Hellman S. Oligometastases revisited. Nature reviews Clinical oncology. 2011; 8:378-382.
16. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70.
17. Hanahan D, Weinberg RA. Hallmarks of cancer : the next generation. Cell. 2011; 144:646-674.
18. Warburg O. On the origin of cancer cells. Science. 1956; 123:309-314.
19. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ. Androgenindependent prostate cancer is a heterogeneous group of diseases : lessons from a rapid autopsy program. Cancer research. 2004; 64:9209-9216.
20. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001; 412:822-826.
21. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002; 419:624-629.
22. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nature genetics. 2003; 33:49-54.
23. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gurel M, Hicks J, Meeker AK, Halushka MK, Simons JW, Isaacs WB, De Marzo AM, Nelson WG, Yegnasubramanian S. Tracking the clonal origin of lethal prostate cancer. The Journal of clinical investigation. 2013; 123:4918-4922.
24. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England journal of medicine. 2012; 366:883-892.
25. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, Titz B, Huang J, Pienta KJ, Graeber TG, Witte ON. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:E4762-4769.
26. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science. 1977; 197:893-895.
27. Chambers AF, Hill RP, Ling V. Tumor heterogeneity and stability of the metastatic phenotype of mouse KHT sarcoma cells. Cancer research. 1981; 41:1368-1372.
28. Harris JF, Chambers AF, Hill RP, Ling V. Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. Proceedings of the National Academy of Sciences of the United States of America. 1982; 79:5547-5551.
29. Cillo C, Dick JE, Ling V, Hill RP. Generation of drugresistant variants in metastatic B16 mouse melanoma cell lines. Cancer research. 1987; 47:2604-2608.
30. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nature reviews Cancer. 2004; 4:448-456.
31. Kendal WS. Oligometastasis as a predictor for occult disease. Mathematical biosciences. 2014; 251:1-10.
32. Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World journal of gastroenterology : WJG. 2001; 7:630-636.
33. Shindo-Okada N, Takeuchi K, Nagamachi Y. Establishment of cell lines with high- and low-metastatic potential from PC-14 human lung adenocarcinoma. Japanese journal of cancer research : Gann. 2001; 92:174-183.
34. Rastogi S, Gulia S, Bajpai J, Ghosh J, Gupta S. Oligometastatic breast cancer : A mini review. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology. 2014; 35:203-206.
35. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G. Clear cell renal cell carcinoma : gene expression analyses identify a potential signature for tumor aggressiveness. Clinical cancer research:an official journal of the American Association for Cancer Research. 2005; 11:5128-5139.
36. Loh J, Davis ID, Martin JM, Siva S. Extracranial oligometastatic renal cell carcinoma : current management and future directions. Future oncology. 2014; 10:761-774.
37. Wuttig D, Baier B, Fuessel S, Meinhardt M, Herr A, Hoefling C, Toma M, Grimm MO, Meye A, Rolle A, Wirth MP. Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. International journal of cancer Journal international du cancer. 2009; 125:474-482.
38. Jones RP, Stattner S, Sutton P, Dunne DF, McWhirter D, Fenwick SW, Malik HZ, Poston GJ. Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. Surgical oncology. 2014; 23:53-60.
39. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, Saltz LB, Weiser M, Solit DB. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012; 30:2956-2962.
40. Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, Wrba F, Gruenberger T. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. The British journal of surgery. 2012; 99:1575-1582.
41. Bruin SC, de Ronde JJ, Wiering B, Braaf LM, de Wilt JH, Vincent AD, van Velthuysen ML, Ruers TJ, Wessels LF LJ. Selection of patients for hepatic surgery of colorectal cancer liver metastasis based on genomic aberrations. Annals of surgical oncology. 2013; 20:S560-569.
42. Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chery L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancerassociated hypoxia. PloS one. 2013; 8:e69239.
43. Huang F, Wu G, Yang K. Oligometastasis and oligo-recurrence : more than a mirage. Radiation oncology. 2014; 9:230.
44. Valastyan S, Weinberg RA. MicroRNAs : Crucial multitasking components in the complex circuitry of tumor metastasis. Cell cycle. 2009; 8:3506-3512.
45. Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, et al. MicroRNA expression characterizes oligometastasis(es). PloS one. 2011; 6:e28650.
46. Uppal A, Wightman SC, Mallon S, Oshima G, Pitroda SP, Zhang Q, Huang X, Darga TE, Huang L, Andrade J, Liu H, Ferguson MK, Greene GL, Posner MC, Hellman S, Khodarev NN, et al. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015; .
47. Hellman S, Weichselbaum RR. Oligometastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1995; 13:8-10.
48. de Vin T, Engels B, Gevaert T, Storme G, De Ridder M. Stereotactic radiotherapy for oligometastatic cancer : a prognostic model for survival. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014; 25:467-471.
49. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver MJ, Minn AJ. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105:18490-18495.
50. Macdermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of oligometastases with radiotherapy. Journal of surgical oncology. 2008; 98:202-206.
51. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F. International guidelines for management of metastatic breast cancer : can metastatic breast cancer be cured? Journal of the National Cancer Institute. 2010; 102:456-463.
52. Uppal A, Weichselbaum RR, Posner MC. Optimizing management of colorectal hepatic metastases : now and in the future. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014; 40:1033-1035.
53. Yao HH, Hong M, Corcoran NM, Siva S, Foroudi F. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia-Pacific journal of clinical oncology. 2014; 10:308-321.
54. Moreno A, Albiach C, Soria R, Vidal V, Gomez R, Antequera M. Oligometastases in prostate cancer : restaging stage IV cancers and new radiotherapy options. Radiation oncology. 2014; 9:258.
55. Reeves F, Murphy D, Evans C, Bowden P, Costello A. Targeted local therapy in oligometastatic prostate cancer :a promising potential opportunity after failed primary treatment. BJU international. 2014; .
56. Bhattasali O, Chen LN, Tong M, Lei S, Collins BT, Krishnan P, Kalhorn C, Lynch JH, Suy S, Dritschilo A, Dawson NA, Collins SP. Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormonenaive prostate cancer. Frontiers in oncology. 2013; 3:293.
57. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. The New England journal of medicine. 2012; 366:925-931.
58. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy : a paradigm shift. Journal of the National Cancer Institute. 2013; 105:256-265.
59. Matzinger P. Tolerance, danger, and the extended family. Annual review of immunology. 1994; 12:991-1045.
60. Matzinger P. The danger model : a renewed sense of self. Science. 2002; 296:301-305.
61. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. Journal of immunology. 2008; 180:3132-3139.
62. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells : changing strategies for cancer treatment. Blood. 2009; 114:589-595.
63. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. Journal of gastrointestinal surgery :official journal of the Society for Surgery of the Alimentary Tract. 2007; 11:1057-1077.
64. Lam VW, Spiro C, Laurence JM, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Annals of surgical oncology. 2012; 19:1292-1301.
65. Deschamps F, Farouil G, Ternes N, Gaudin A, Hakime A, Tselikas L, Teriitehau C, Baudin E, Auperin A, de Baere T. Thermal ablation techniques : a curative treatment of bone metastases in selected patients? European radiology. 2014; 24:1971-1980.
66. Solomon LA, Munkarah AR, Vorugu VR, Deppe G, Adam B, Malone JM, Jr., Littrup PJ. Image-guided percutaneous cryotherapy for the management of gynecologic cancer metastases. Gynecologic oncology. 2008; 111:202-207.
67. Littrup PJ, Bang HJ, Currier BP, Goodrich DJ, Aoun HD, Heilbrun LK, Adam BA. Soft-tissue cryoablation in diffuse locations : feasibility and intermediate term outcomes. Journal of vascular and interventional radiology : JVIR. 2013; 24:1817-1825.
68. van Dongen JA, van Slooten EA. The surgical treatment of pulmonary metastases. Cancer treatment reviews. 1978; 5:29-48.
69. Institute NC. PDQ(R) Levels of Evidence for Adult and Pediatric Cancer Treatment Studies. (Bethesda, MD :National Cancer Institute).
70. Camacho LH, Kurzrock R, Cheung A, Barber DF, Gupta S, Madoff DC, Wallace MJ, Kim EE, Curley SA, Hortobagyi GN, Mavligit G. Pilot study of regional, hepatic intra-arterial paclitaxel in patients with breast carcinoma metastatic to the liver. Cancer. 2007; 109:2190-2196.
71. Bojko P, Welt A, Schleucher R, Borquez D, Scheulen ME, Vanhoefer U, Poettgen C, Stuschke M, Broelsch CE, Stamatis G, Wilke H, Seeber S, Harstrick A. High-dose chemotherapy with autologous stem cell transplantation in patients with oligometastatic breast cancer. Bone marrow transplantation. 2004; 34:637-643.
72. Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast cancer research and treatment. 2009; 115:601-608.
73. Kobayashi T, Ichiba T, Sakuyama T, Arakawa Y, Nagasaki E, Aiba K, Nogi H, Kawase K, Takeyama H, Toriumi Y, Uchida K, Kobayashi M, Kanehira C, Suzuki M, Ando N, Natori K, et al. Possible clinical cure of metastatic breast cancer : lessons from our 30-year experience with oligometastatic breast cancer patients and literature review. Breast cancer. 2012; 19:218-237.
74. Mimoto R, Kobayashi T, Imawari Y, Kamio M, Kato K, Nogi H, Toriumi Y, Hirooka S, Uchida K, Takeyama H. Clinical relevance and low tumor-initiating properties of oligometastatic breast cancer in pulmonary metastasectomy. Breast cancer research and treatment. 2014; 147:317-324.
75. VanderWalde A, Ye W, Frankel P, Asuncion D, Leong L, Luu T, Morgan R, Twardowski P, Koczywas M, Pezner R, Paz IB, Margolin K, Wong J, Doroshow JH, Forman S, Shibata S, et al. Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012; 18:1273-1280.
76. Bourgier C, Khodari W, Vataire AL, Pessoa EL, Dunant A, Delaloge S, Uzan C, Balleyguier C, Mathieu MC, Marsiglia H, Arriagada R. Breast radiotherapy as part of loco-regional treatments in stage IV breast cancer patients with oligometastatic disease. Radiotherapy and oncology :journal of the European Society for Therapeutic Radiology and Oncology. 2010; 96:199-203.
77. Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Baron A, Razook C, Matthes S, Bearman SI. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002; 20:707-718.
78. Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung cancer. 2013; 82:197-203.
79. Lanuti M, Sequist LV, Sharma A, Mino-Kenudson M. Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer. The New England journal of medicine. 2011; 365:1426-1435.
80. Grossi F, Kubota K, Cappuzzo F, de Marinis F, Gridelli C, Aita M, Douillard JY. Future scenarios for the treatment of advanced non-small cell lung cancer : focus on taxanecontaining regimens. The oncologist. 2010; 15:1102-1112.
81. Strong VE, D'Angelica M, Tang L, Prete F, Gonen M, Coit D, Touijer KA, Fong Y, Brennan MF. Laparoscopic adrenalectomy for isolated adrenal metastasis. Annals of surgical oncology. 2007; 14:3392-3400.
82. Collen C, Christian N, Schallier D, Meysman M, Duchateau M, Storme G, De Ridder M. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2014; 25:1954-1959.
83. De Ruysscher D, Wanders R, van Baardwijk A, Dingemans AM, Reymen B, Houben R, Bootsma G, Pitz C, van Eijsden L, Geraedts W, Baumert BG, Lambin P. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases : long-term results of a prospective phase II trial (Nct01282450). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012; 7:1547-1555.
84. Nieder C, Tollali T, Reigstad A, Pawinski A, Haukland E, Dalhaug A. Oligometastatic non-small cell lung cancer : a significant entity outside of specialized cancer centers? Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2014; 23:526-531.
85. Khan AJ, Mehta PS, Zusag TW, Bonomi PD, Penfield Faber L, Shott S, Abrams RA. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2006; 81:163-167.
86. Ashworth AB, Senan S, Palma DA, Riquet M, Ahn YC, Ricardi U, Congedo MT, Gomez DR, Wright GM, Melloni G, Milano MT, Sole CV, De Pas TM, Carter DL, Warner AJ, Rodrigues GB. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clinical lung cancer. 2014; 15:346-355.
87. Lopez Guerra JL, Gomez D, Zhuang Y, Hong DS, Heymach JV, Swisher SG, Lin SH, Komaki R, Cox JD, Liao Z. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. International journal of radiation oncology, biology, physics. 2012; 84:e61-67.
88. Collaud S, Stahel R, Inci I, Hillinger S, Schneiter D, Kestenholz P, Weder W. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage. Lung cancer. 2012; 78:234-238.
89. Congedo MT, Cesario A, Lococo F, De Waure C, Apolone G, Meacci E, Cavuto S, Granone P. Surgery for oligometastatic non-small cell lung cancer : long-term results from a single center experience. The Journal of thoracic and cardiovascular surgery. 2012; 144:444-452.
90. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, Shah N, Hoffman PC, Chmura SJ, Connell PP, Vokes EE, Weichselbaum RR, Salama JK. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012; 7:376-381.
91. Griffioen GH, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB, Slotman BJ, Yaremko BP, Senan S, Palma DA. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC) : patient outcomes and prognostic factors. Lung cancer. 2013; 82:95-102.
92. Yano T, Okamoto T, Haro A, Fukuyama S, Yoshida T, Kohno M, Maehara Y. Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung cancer. 2013; 82:431-435.
93. Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013; 8:346-351.
94. Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, Sher DJ, Arvold ND, Baldini EH, Chen AB, Kozono DE, Swanson SJ, Jackman DM, Alexander BM. Aggressive therapy for patients with nonsmall cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung cancer. 2014; 85:239-244.
95. Cheufou DH, Welter S, Chalvatzoulis E, Christof D, Theegarten D, Stamatis G. Surgery of primary lung cancer with oligometastatic m1b synchronous single brain metastasis : analysis of 37 cases. The Thoracic and cardiovascular surgeon. 2014; 62:612-615.
96. Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM, Lo PC, Baldini EH, Johnson BE, Chen AB. Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. International journal of radiation oncology, biology, physics. 2014; 89:880-887.
97. Sheu T, Heymach JV, Swisher SG, Rao G, Weinberg JS, Mehran R, McAleer MF, Liao Z, Aloia TA, Gomez DR. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. International journal of radiation oncology, biology, physics. 2014; 90:850-857.
98. Tonnies M, Pfannschmidt J, Bauer TT, Kollmeier J, Tonnies S, Kaiser D. Metastasectomy for synchronous solitary non-small cell lung cancer metastases. The Annals of thoracic surgery. 2014; 98:249-256.
99. Ouyang WW, Su SF, Ma Z, Hu YX, Lu B, Li QS, Geng YC, Li HQ. Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy. Radiation oncology. 2014; 9:147.
100. Endo C, Hasumi T, Matsumura Y, Sato N, Deguchi H, Oizumi H, Sagawa M, Tsushima T, Takahashi S, Shibuya J, Hirose M, Kondo T. A prospective study of surgical procedures for patients with oligometastatic non-small cell lung cancer. The Annals of thoracic surgery. 2014; 98:258-264.
101. Essner R, Lee JH, Wanek LA, Itakura H and Morton DL. Contemporary surgical treatment of advanced-stage melanoma. Archives of surgery. 2004; 139:961-966; discussion 966-967.
102. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. Journal of neurosurgery. 2012; 117:227-233.
103. Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE, Oberneder R, Rothenberger KH, Stief CG, Holzel D. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. European urology. 2010; 57:754-761.
104. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. CA: a cancer journal for clinicians. 2009; 59:225-249.
105. Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA and Lu D. Local surgical, ablative, and radiation treatment of metastases. CA : a cancer journal for clinicians. 2009; 59:145-170.
106. Engels B, Gevaert T, Everaert H, De Coninck P, Sermeus A, Christian N, Storme G, Verellen D, De Ridder M. Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer. Radiation oncology. 2012; 7:34.
107. Hughes KS, Simon R, Songhorabodi S, Adson MA, Ilstrup DM, Fortner JG, Maclean BJ, Foster JH, Daly JM, Fitzherbert D, et al. Resection of the liver for colorectal carcinoma metastases : a multi-institutional study of patterns of recurrence. Surgery. 1986; 100:278-284.
108. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996; 77:1254-1262.
109. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer : analysis of 1001 consecutive cases. Ann Surg. 1999; 230:309-318. discussion 318-321.
110. Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, Curley SA, Loyer EM, Muratore A, Mentha G, Capussotti L, Vauthey JN. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005; 241:715-722. discussion 722-714.
111. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007; 25:4575-4580.
112. Dellas K, Reese T, Richter M, Arnold D, Dunst J. Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer : results of a phase I study. Radiation oncology. 2012; 7:83.
113. Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RL, Navarria P, Ascolese A, Tozzi A, Iftode C, De Rose F, Villa E, Personeni N, Rimassa L, Santoro A, Fogliata A, Mancosu P, et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer : a safe and effective approach. BMC cancer. 2014; 14:619.
114. Salah S, Watanabe K, Welter S, Park JS, Park JW, Zabaleta J, Ardissone F, Kim J, Riquet M, Nojiri K, Gisabella M, Kim SY, Tanaka K, Al-Haj Ali B. Colorectal cancer pulmonary oligometastases : pooled analysis and construction of a clinical lung metastasectomy prognostic model. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012; 23:2649-2655.
115. Van den Begin R, Engels B, Gevaert T, Duchateau M, Tournel K, Verellen D, Storme G, De Ridder M. Impact of inadequate respiratory motion management in SBRT for oligometastatic colorectal cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014; 113:235-239.
116. Filippi AR, Badellino S, Ceccarelli M, Guarneri A, Franco P, Monagheddu C, Spadi R, Ragona R, Racca P, Ricardi U. Stereotactic Ablative Radiation Therapy as First Local Therapy for Lung Oligometastases From Colorectal Cancer : A Single-Institution Cohort Study. International journal of radiation oncology, biology, physics. 2014.
117. Salah S, Watanabe K, Park JS, Addasi A, Park JW, Zabaleta J, Ardissone F, Kim J, Riquet M, Nojiri K, Gisabella M, Kim SY, Tanaka K. Repeated resection of colorectal cancer pulmonary oligometastases : pooled analysis and prognostic assessment. Annals of surgical oncology. 2013; 20:1955-1961.
118. Bae SH, Kim MS, Cho CK, Kang JK, Kang HJ, Kim YH, Shin US, Moon SM, Lee DH. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. Journal of surgical oncology. 2012; 106:138-143.
119. Kang JK, Kim MS, Kim JH, Yoo SY, Cho CK, Yang KM, Yoo HJ, Seo YS, Lee DH, Kang HJ, Kim YH, Shin US. Oligometastases confined one organ from colorectal cancer treated by SBRT. Clinical & experimental metastasis. 2010; 27:273-278.
120. Hohenberger P, Kasper B, Ahrar K. Surgical management and minimally invasive approaches for the treatment of metastatic sarcoma. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2013; :457-464.
121. Falk AT, Moureau-Zabotto L, Ouali M, Penel N, Italiano A, Bay JO, Olivier T, Sunyach MP, Boudou-Roquette P, Salas S, Le Maignan C, Ducassou A, Isambert N, Kalbacher E, Pan C, Saada E, et al. Effect on survival of local ablative treatment of metastases from sarcomas : a study of the French sarcoma group. Clinical oncology. 2015; 27:48-55.
122. Rhomberg W, Eiter H, Schmid F, Saely CH. Combined vindesine and razoxane shows antimetastatic activity in advanced soft tissue sarcomas. Clinical & experimental metastasis. 2008; 25:75-80.
123. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. The New England journal of medicine. 1996; 335:865-875.
124. Ranck MC, Golden DW, Corbin KS, Hasselle MD, Liauw SL, Stadler WM, Hahn OM, Weichselbaum RR, Salama JK. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. American journal of clinical oncology. 2013; 36:589-595.
125. Thibault I, Al-Omair A, Masucci GL, Masson-Cote L, Lochray F, Korol R, Cheng L, Xu W, Yee A, Fehlings MG, Bjarnason GA, Sahgal A. Spine stereotactic body radiotherapy for renal cell cancer spinal metastases : analysis of outcomes and risk of vertebral compression fracture. Journal of neurosurgery Spine. 2014; 21:711-718.
126. Bang HJ, Littrup PJ, Goodrich DJ, Currier BP, Aoun HD, Heilbrun LK, Vaishampayan U, Adam B, Goodman AC. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control : feasibility, outcomes, and estimated cost-effectiveness for palliation. Journal of vascular and interventional radiology : JVIR. 2012; 23:770-777.
127. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferonalfa- based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma : a randomised trial. Lancet. 2001; 358:966-970.
128. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renalcell cancer. The New England journal of medicine. 2001; 345:1655-1659.
129. Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, Vickers A, Scardino PT. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer : a comparison of clinical cohorts adjusted for case mix. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010; 28:1508-1513.
130. Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. European urology. 2012; 62:204-209.
131. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/ SFUO-3) : an open randomised phase III trial. Lancet. 2009; 373:301-308.
132. Cadeddu JA, Partin AW, Epstein JI, Walsh PC. Stage D1 (T1-3, N1-3, M0) prostate cancer : a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology. 1997; 50:251-255.
133. Shao YH, Kim S, Moore DF, Shih W, Lin Y, Stein M, Kim IY, Lu-Yao GL. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients : results of a population-based, propensity score-matched analysis. European urology. 2014; 65:693-700.
134. Pierorazio PM, Lin BM, Mullins JK, Hyndman ME, Schaeffer EM, Han M, Partin AW, Pavlovich CP. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. Urologic oncology. 2013; 31:589-594.
135. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M, 3rd, Briganti A. Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer : A Systematic Review of the Literature. European urology. 2014.
136. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. European urology. 2014; 65:1058-1066.
137. Zapatero A, Guerrero, A., Maldonado, J. , Alvarez, A., San Segundo, C.G., Rodriguez, M.C., Macias, V., Pedro-Olive, A., Casas, F., Boladeras, A., de Vidales, C.M., de la Torre, M.V., Calvo, F.A. Randomized Phase III Trial of Adjuvant Androgen Deprivation in Combination with High-dose Conformal Radiotherapy in Intermediate and High Risk Localized Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014; 32:52.
138. McKay RR, Choueiri TK, Taplin ME. Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer. Drugs. 2013; 73:1417-1430.
139. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF, McLaren D, Parker CC, Parmar MK, Ritchie AW, Russell JM, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era" : Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European urology. 2014.
140. Maximum androgen blockade in advanced prostate cancer. an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000; 355:1491-1498.
141. Heidenreich A, Pfister D, Brehmer B, Porres D. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases : Results of a first feasibility and case control study]. Der Urologe Ausg A. 2015; 54:14-21.
142. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Vizziello D, Sun M, Karakiewicz PI, Menon M, Montorsi F, Briganti A. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014; 32:3939-3947.
143. Schick U, Jorcano S, Nouet P, Rouzaud M, Vees H, Zilli T, Ratib O, Weber DC, Miralbell R. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta oncologica. 2013; 52:1622-1628.
144. Ost P, Decaestecker K, Lambert B, Fonteyne V, Delrue L, Lumen N, Ameye F, De Meerleer G. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. The Prostate. 2014; 74:297-305.
145. Ponti E, Ingrosso G, Carosi A, Di Murro L, Lancia A, Pietrasanta F, Santoni R. Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis : A Single-Center Experience. Clinical genitourinary cancer. 2014.
146. Decaestecker K, De Meerleer G, Lambert B, Delrue L, Fonteyne V, Claeys T, De Vos F, Huysse W, Hautekiet A, Maes G, Ost P. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiation oncology. 2014; 9:135.
147. Ahmed KA, Barney BM, Davis BJ, Park SS, Kwon ED, Olivier KR. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Frontiers in oncology. 2012; 2:215.
148. Berkovic P, De Meerleer G, Delrue L, Lambert B, Fonteyne V, Lumen N, Decaestecker K, Villeirs G, Vuye P, Ost P. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases : deferring androgen deprivation therapy. Clinical genitourinary cancer. 2013; 11:27-32.
149. Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R, Fossati Ing P, Gherardi F, Alterio D, Zerini D, Garibaldi C, Baroni G, De Cobelli O, Orecchia R. Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. American journal of clinical oncology. 2014; 37:227-233.
150. Tabata K, Niibe Y, Satoh T, Tsumura H, Ikeda M, Minamida S, Fujita T, Ishii D, Iwamura M, Hayakawa K, Baba S. Radiotherapy for oligometastases and oligo-recurrence of bone in prostate cancer. Pulmonary medicine. 2012; 2012:541656.
151. Singh D, Yi WS, Brasacchio RA, Muhs AG, Smudzin T, Williams JP, Messing E, Okunieff P. Is there a favorable subset of patients with prostate cancer who develop oligometastases? International journal of radiation oncology, biology, physics. 2004; 58:3-10.
152. Decaestecker K, De Meerleer G, Ameye F, Fonteyne V, Lambert B, Joniau S, Delrue L, Billiet I, Duthoy W, Junius S, Huysse W, Lumen N, Ost P. Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP) : study protocol for a randomized phase II trial. BMC cancer. 2014; 14:671.
153. Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, Dearnaley DP, Parker CC, Ritchie AW, Russell JM, Thalmann G, Cassoly E, Millman R, Matheson D, Schiavone F, Spears MR, et al. Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. European urology. 2014.
154. Health USNIo. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US). 2000-.
155. Hospital CUoHKPYNE. ATOM_local Ablative Therapy. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) :National Library of Medicine (US) 2000-.
156. Institute RPCINC. Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Nonsmall Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
157. University CCCoWF. Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
158. Institute NCCTGNC. Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
159. Oncology MR. Concurrent and Non-concurrent Chemo-radiotherapy or Radiotherapy Alone for Patients With Oligo-metastatic Stage IV Non-small Cell Lung Cancer (NSCLC). In:ClinicalTrials.gov [Internet]. Bethesda (MD) :National Library of Medicine (US)2000-.
160. Institute SCHaR. The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer-NSCLC) (OITROLC). In: ClinicalTrials. gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
161. Foundation WJM. The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Secondline Treatment (ROLE). In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
162. Pennsylvania ACCotUo. Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
163. Center MDAC. Oligometastatic Disease. In: ClinicalTrials. gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
164. Florida Uo. Radiotherapy for Oligometastatic Prostate Cancer. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) :National Library of Medicine (US) 2000-.
165. Clinic M. Monitoring Anti-Prostate Cancer Immunity Following Stereotactic Body Radiotherapy (SBRT). In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
166. Castellon GdICeORHPd. Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer. In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
167. Dresden TU. Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma (Oli-P). In: ClinicalTrials.gov [Internet]. (Bethesda (MD) :National Library of Medicine (US) 2000-.
168. l'Ouest ICd. Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS). In: ClinicalTrials. gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
169. Institute CoHMCNC. Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Androgen Deprivation Therapy for Metastatic Prostate Cancer. In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
170. University Hospital G. Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer. In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
171. Center MS-KC. Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
172. Institute TNC. High Dose Chemotherapy in Oligometastatic Homologous Recombination Deficient Breast Cancer. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) :National Library of Medicine (US) 2000-.
173. Peter MacCallum Cancer Centre A. A Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475. (BOSTON II). In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
174. Gustave Roussy CC Grand Paris. Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer (STEREO-SEIN). In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
175. Institute CoHMCNC. Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer. In ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
176. Center ULCC. Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
177. Institute UoCNC. Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
178. Nevada CCCo. Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
179. Center OSUCC. Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
180. Center MDAC. Combi-Neo Study for Stage IV Melanoma. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) :National Library of Medicine (US) 2000-.
181. Center SKCC. Stereotactic Body Radiation With Nelfinavir for Oligometastases. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
182. Dwight Heron UoP. Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation. In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
183. Dwight Heron UoP. Radiosurgery for Patients Recurrent Oligometastatic Disease. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
184. Brussel UZ. Non-interventional Observational Study of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Cancer. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
185. University Health Network TPMH, Canada. 5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases. In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
186. Center UoTSM. Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation. In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
187. Centers RMC. Definitive Therapy for Oligometastatic Solid Malignancies. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
188. Medicine MSSo. Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
189. Oncology MR. Assessment of Toxicity of the Immunocytokine L19-IL2 Administered Directly After the Course of Stereotactic Ablative Body Radiotherapy in Patients Suffering From Oligometastatic Solid Tumour. In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
190. (TROG) T-TROG. A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung, (TROG 13.01 SAFRON II). In: ClinicalTrials. gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
191. Lawson Health Research Institute; London Regional Cancer Program CVUoA. Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET). In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
192. Medicine WUSo. Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
193. St. John's Mercy Research Institute SLICgI. Stereotactic Body Radiotherapy for Liver Tumors. (Bethesda (MD) :National Library of Medicine (US) 2000-.
194. Hamburg-Eppendorf U. Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer (OLGA). In:ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
195. Center SKCC. Stereotactic Radiation Therapy for Pediatric Sarcomas. In: ClinicalTrials.gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000-.
196. Niibe Y, Hayakawa K. Oligometastases and oligo-recurrence : the new era of cancer therapy. Japanese journal of clinical oncology. 2010; 40:107-111.
197. Niibe Y, Chang JY. Novel insights of oligometastases and oligo-recurrence and review of the literature. Pulmonary medicine. 2012; 2012:261096.
198. Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, Weichselbaum R. The oligometastatic state - separating truth from wishful thinking. Nature reviews Clinical oncology. 2014; 11:549-557.
199. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, et al. Prostate cancer, version 1.2014. Journal of the National Comprehensive Cancer Network : JNCCN. 2013; 11:1471-1479.
200. Center CoHM. Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Androgen Deprivation Therapy for Metastatic Prostate Cancer. In: ClinicalTrials. gov [Internet]. (Bethesda (MD) : National Library of Medicine (US) 2000